Core Viewpoint - He Eye Hospital's refractive business is projected to achieve revenue of 135 million yuan in the first half of 2025, reflecting a year-on-year growth of 3.26%, indicating a return to a growth trajectory [1] Group 1: Business Performance - The refractive surgery average selling price (ASP) is on the rise due to an increased proportion of high-value procedures such as femtosecond laser and ICL crystal implantation [1]

Core Viewpoint - He Eye Hospital (301103) expects a net profit attributable to shareholders of 24 million to 36 million for 2025, representing a year-on-year growth of 187.60% to 231.40% [1] Group 1: Performance Improvement - The company has achieved a turnaround from loss to profit during the reporting period, driven by business structure optimization, effective cost control, and the disposal of inefficient assets [1] - Significant enhancement in profitability is attributed to the continuous optimization of the business structure, with a focus on high-margin refractive and optical businesses [1] Group 2: Cost and Efficiency Management - The company has implemented refined operational management, achieving cost reduction and efficiency improvement through centralized procurement optimization, supply chain efficiency enhancement, and digital operations [1] - These measures have contributed to the overall improvement in profitability [1] Group 3: Asset Optimization - The company has actively integrated, adjusted, or divested certain business units that have long-term poor performance or weak strategic synergy, further optimizing asset allocation efficiency [1]

Core Viewpoint - The company is expected to turn a profit in 2025, reversing previous losses due to optimized business structure, effective cost control, and the clearing of inefficient assets [1][2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a turnaround from loss to profit, indicating a positive shift in financial performance [1]. Group 2: Reasons for Performance Change - Continuous optimization of the business structure has driven growth, particularly in high-margin refractive and optical businesses [2]. - Significant results from cost and expense management have been achieved through refined operational management, centralized procurement, and enhanced supply chain efficiency [2]. - The company has actively integrated, adjusted, or divested underperforming business units to improve asset allocation efficiency [2]. Group 3: Additional Information - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by an accounting firm [3]. - Final financial data will be disclosed in the company's 2025 annual report [3].

报告期内，公司业绩实现扭亏为盈，得益于业务结构优化、成本费用有效控制及低效资产出清，公司盈 利能力显著增强，具体原因如下：1.持续优化业务结构，高毛利业务驱动增长：公司推进业务结构优 化，加大对高毛利的屈光业务与视光业务的投入和发展所致。2.成本与费用管控成效显著：公司全面推 行精细化运营管理，通过集中采购优化、供应链效率提升、数字化运营等赋能，实现降本增效，从而带 动了整体盈利能力的提升。3.推进低效资产出清：公司对部分长期效益不佳或战略协同性较弱的业务单 元实施了主动整合、调整或剥离，进一步优化了资产配置效率。 格隆汇1月27日丨何氏眼科(301103.SZ)公布，预计2025年归属于上市公司股东的净利润2,400万元–3,600 万元，同比扭亏为盈，扣除非经常性损益后的净利润1,100万元–1,650万元，同比扭亏为盈。 ...

Core Viewpoint - The resignation of Zhou Jinfeng, the company's director and board secretary, is noted, and the company is taking steps to ensure continuity in its operations and governance [1] Group 1: Management Changes - Zhou Jinfeng submitted a written resignation report due to personal reasons, effective immediately upon delivery [1] - Zhou will no longer hold any position within the company after his resignation [1] - The company’s general manager, He Xingru, will temporarily assume the duties of the board secretary until a new appointment is made [1] Group 2: Financial Performance - For the period from January to September 2025, the company reported revenue of 855 million yuan, a year-on-year decrease of 1.11% [1] - The net profit attributable to shareholders for the same period was 54 million yuan, reflecting a significant year-on-year increase of 232.18% [1] - The increase in net profit is attributed to the company's focus on enhancing medical services, optimizing the supply chain, and reducing operational costs through various measures [1]

Core Viewpoint - The report from CITIC Securities indicates that Aier Eye Hospital's performance in H1 2025 outpaced the industry, with an estimated contribution of 8 percentage points to revenue growth from hospital acquisitions in 2024 [1] Group 1: Revenue Growth - There is a significant divergence in revenue growth between Q1 and Q2, primarily influenced by fluctuations in refractive surgery business [1] - The company expects multiple factors to positively impact business in the second half of 2025, including an anticipated increase in the penetration rate of new refractive surgery techniques, which is expected to stabilize and improve gross margins [1] Group 2: Cost and Profitability - The impact of cataract centralized procurement is projected to gradually dissipate by Q3 2025 [1] - New business trials such as presbyopia clinics and dry eye treatments are expected to become new growth engines for the company in the latter half of 2025 and beyond [1] - Due to economies of scale, the net profit growth in H2 2025 is expected to outpace revenue growth [1] Group 3: Investment Rating - The report maintains a "Buy" rating for the company [1]

Core Viewpoint - Huaxia Eye Hospital (301267) is focusing on increasing the revenue share from refractive, optical, and presbyopia services to 70%-80% in the future, currently standing at approximately 40% for these services and 60% for cataract and other eye disease services [1] Group 1 - The current revenue distribution for Huaxia Eye Hospital's Beijing branch is approximately 40% from refractive and optical services and 60% from cataract and other eye disease services [1] - The company is intensifying efforts to develop refractive, optical, and presbyopia services [1] - The target for future revenue composition is to achieve a 70%-80% share from refractive, optical, and presbyopia services [1]

Group 1: Business Overview - The company's current medical insurance business accounts for a low proportion of overall revenue, with ongoing reforms in payment methods and centralized procurement policies impacting short-term performance [2][3] - The company has identified 24 key investment provinces for future expansion, utilizing both self-built and acquisition strategies to establish a network of ophthalmic medical services [3][4] Group 2: Revenue Structure - In the first half of 2025, the revenue breakdown is as follows: Refractive business at 36.90%, Vision care at 24.04%, Cataract business at 20.14%, and Posterior segment business at 12.94% [4] Group 3: Market Trends - The aging population is driving long-term demand for age-related eye diseases, while the national strategy for myopia prevention remains a challenge for children and adolescents [5] - The penetration rate of eye disease diagnosis in China is still low compared to developed countries, indicating significant market potential for the ophthalmic medical service industry [5] Group 4: Technological Advancements - The company is collaborating with smart hardware firms to explore the application potential of AI glasses in ophthalmic medical services [6][7] - Multiple smart medical platforms have been established to enhance diagnostic and treatment services, including the Eye Tong Smart Diagnosis Service Platform 3.0 and a 5G remote diagnosis platform [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Insights - The company reported a revenue of 2.139 billion yuan for H1 2025, representing a year-over-year increase of 4.31%, and a net profit attributable to shareholders of 282 million yuan, up 6.20% year-over-year [4][10] - The introduction of new surgical techniques has significantly boosted the company's refractive business, leading to a revenue of 789 million yuan in H1 2025, which is a 13.75% increase year-over-year [12] - The company has established a nationwide medical network with 64 specialized eye hospitals and 67 vision centers, enhancing its service coverage across various regions [13] Financial Performance Summary - For H1 2025, the company's gross margin was 45.20%, a slight decrease of 0.64 percentage points year-over-year, but improved in Q2 2025 to 45.44%, reflecting a recovery from previous impacts [11] - The company expects revenues for 2025-2027 to be 4.379 billion, 4.878 billion, and 5.479 billion yuan respectively, with year-over-year growth rates of 8.74%, 11.39%, and 12.32% [14] - The net profit attributable to shareholders is projected to be 570 million, 692 million, and 811 million yuan for the same period, with growth rates of 33.05%, 21.27%, and 17.21% respectively [14]

Summary of Medical Services Industry Conference Call Industry Overview - The medical services industry experienced a slight revenue increase of 0.2% to 36 billion in the first half of 2024, with a decline in the second quarter due to high base effects from the previous year [1][2] - Consumer medical services, particularly in ophthalmology, showed resilience, while serious medical service companies faced a revenue decline of 15%-20% due to high base effects and DRG/DIP consulting fees [1][4] Key Insights and Arguments - **Ophthalmology Sector Performance**: - Aier Eye Hospital's refractive and optical businesses achieved double-digit growth, leading the industry [1][5] - Other companies in the cataract business experienced declines due to the impact of crystal procurement, but a recovery is expected in the second half of the year [1][5] - The price war in refractive services is diminishing, and the demand for optical services is expected to rise due to the conclusion of the youth myopia prevention plan [1][5][8] - **Medicare Policy Impact**: - From January to July, the Medicare fund showed stable income growth of 7% and a spending decrease of 1%, indicating pressure on the expenditure side [9] - Data from cities like Chongqing, Tianjin, and Guangxi suggest steady outpatient visits, with expectations for recovery in demand and reporting in the second half of the year [9] - **Aier Eye Hospital's Strategic Expansion**: - The company aims to increase its overseas market share from the current 10-15% to 30-50% [1][10] - New business opportunities include advanced refractive procedures, multi-focus cataract upgrades, and presbyopia surgeries, with AI technology expected to enhance operational efficiency [1][10] Company-Specific Performance - **Aier Eye Hospital**: - Reported a 9% revenue growth and a 14% increase in net profit excluding non-recurring items in the first half of 2024 [3][8] - The average selling price (ASP) in refractive services increased by approximately 5% [5][8] - **International Medical**: - Faced operational pressure with a 16% revenue decline but managed to reduce net profit loss by 15% through improved diagnostic efficiency and optimized inpatient services [3][11] - The proton center is set to commence operations, and the aesthetic medical business is expected to grow significantly [11] Future Development Expectations - The second half of 2024 is anticipated to show optimistic trends for the medical services industry, with potential stock price opportunities due to accelerated company performance [3][12] - Policy changes, such as the introduction of provincial payment details and the expansion of prepayment and real-time settlement, are expected to positively impact the industry [12][13] - The overall beta slope of the industry is expected to improve, indicating a recovery in company performance and elasticity [13]